Buspirone Hydrochloride
NDC Package 67046-149-07

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Buspirone Hydrochloride is diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Marketed by Contract Pharmacy Services-pa, this product is identified by NDC 67046-149 and is authorized under FDA application ANDA076008.

Identification & Billing

NDC Package Code
67046-149-07
Package Description
7 TABLET in 1 BLISTER PACK
Product Code
67046-149
11-Digit Billing Format
67046014907
RxNorm Crosswalk
RxCUI: 197500 - chlorthalidone 50 MG Oral Tablet

Clinical Specifications

Proprietary Name
Buspirone Hydrochloride
Dosage Form
-
Usage Information
Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy  The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see  PRECAUTIONS, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate.

Regulatory & Marketing

Labeler Name
Contract Pharmacy Services-pa
FDA Application #
ANDA076008
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-19-2017
Listing Expiration
12-31-2021
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (67046-149). Click a package code to view its specific billing and regulatory data.

67046-149-14
14 TABLET in 1 BLISTER PACK
67046-149-15
15 TABLET in 1 BLISTER PACK
67046-149-21
21 TABLET in 1 BLISTER PACK
67046-149-28
28 TABLET in 1 BLISTER PACK
67046-149-30
30 TABLET in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67046-149-07 identifies a specific commercial package of 7 tablet in 1 blister pack of Buspirone Hydrochloride, labeled by Contract Pharmacy Services-pa. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Contract Pharmacy Services-pa on September 19, 2017. The current certification is valid through December 31, 2021.

How is this Contract Pharmacy Services-pa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67046014907. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
67046-149-07
11-Digit CMS (5-4-2)
67046-0149-07

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.